€10.35
0.19% yesterday
Madrid, Jun 30, 05:35 pm CET
ISIN
ES0171996087
Symbol
GRF
Sector
Industry

Grifols Stock price

€10.35
+0.88 9.29% 1M
+1.17 12.70% 6M
+1.20 13.14% YTD
+2.22 27.37% 1Y
-7.69 42.61% 3Y
-16.68 61.71% 5Y
-7.72 42.71% 10Y
+7.81 306.68% 20Y
Madrid, Closing price Mon, Jun 30 2025
+0.02 0.19%
ISIN
ES0171996087
Symbol
GRF
Sector
Industry

Key metrics

Basic
Market capitalization
€6.2b
Enterprise Value
€15.3b
Net debt
€9.0b
Cash
€1.0b
Shares outstanding
680.4m
Valuation (TTM | estimate)
P/E
35.62 | 13.21
P/S
0.85 | 0.81
EV/Sales
2.07 | 1.98
EV/FCF
22.45
P/B
1.25
Dividends
DPS
€0.00
Yield 1Y | 5Y
0.00% | 0.62%
Growth 1Y | 5Y
- | -100.00%
Payout 1Y | 3Y
0.00% | 0.00%
Increased
0 Years
Financials (TTM | estimate)
Revenue
€7.4b | €7.7b
EBITDA
€2.3b | €1.9b
EBIT
€1.2b
Net Income
€195.2m | €532.0m
Free Cash Flow
€681.1m
Growth (TTM | estimate)
Revenue
10.76% | 7.14%
EBITDA
140.47% | 47.45%
EBIT
39.00%
Net Income
13.86% | 239.04%
Free Cash Flow
200.27%
Margin (TTM | estimate)
Gross
38.77%
EBITDA
31.53% | 25.18%
EBIT
16.65%
Net
2.65% | 6.89%
Free Cash Flow
9.24%
Financial Health
Equity Ratio
27.49%
Return on Equity
2.67%
ROCE
6.53%
ROIC
-
Debt/Equity
1.78
More
EPS
€0.29
FCF per Share
€1.00
Short interest
-
Employees
23.83k
Rev per Employee
€300.00k
Show more

Is Grifols a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,948 stocks worldwide.

Grifols Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Grifols forecast:

12x Buy
63%
5x Hold
26%
2x Sell
11%

Analyst Opinions

19 Analysts have issued a Grifols forecast:

Buy
63%
Hold
26%
Sell
11%

Financial data from Grifols

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
7,372 7,372
11% 11%
100%
- Direct Costs 4,514 4,514
10% 10%
61%
2,858 2,858
12% 12%
39%
- Selling and Administrative Expenses 1,213 1,213
2% 2%
16%
- Research and Development Expense 368 368
4% 4%
5%
2,325 2,325
140% 140%
32%
- Depreciation and Amortization 1,097 1,097
1,215% 1,215%
15%
EBIT (Operating Income) EBIT 1,228 1,228
39% 39%
17%
Net Profit 195 195
14% 14%
3%

In millions EUR.

Don't miss a Thing! We will send you all news about Grifols directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Head office Spain
CEO Nacho Abia
Employees 23,833
Founded 1940
Website www.grifols.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today